This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- ERLEADA (apalutamide) is an androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. ERLEADA inhibits AR nuclear translocation, inhibits DNA binding, and impedes AR-mediated transcription.1-3
- No cases of PRES in patients treated with ERLEADA have been described in the published clinical studies.
- A retrospective real-world study in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) described the incidence of central nervous system (CNS)-related clinical outcomes (including posterior reversible encephalopathy syndrome [PRES]) among patients with nmCRPC treated with ERLEADA, darolutamide, or enzalutamide.4
CLINICAL DATA
- No prospective, randomized, clinical trials reporting the incidence of PRES among patients treated with ERLEADA have been published.
Additional data
Retrospective Real-World Study in Patients with nmCRPC
Lledo et al (2025)4 conducted a retrospective real-world, descriptive analysis to describe newly diagnosed CNS-related outcomes, including PRES, among US-based patients with nmCRPC treated with ERLEADA (n=253), darolutamide (n=544), or enzalutamide (n=645). Concomitant use of androgen deprivation therapy was not required for inclusion. The mean duration of the on-treatment observation period was 12.4 months in the ERLEADA group. The proportion of patients who experienced new onset CNS-related conditions in the ERLEADA cohort at 12 months and 24 months post-index were 25.7% and 46.6%, respectively. PRES was not included in the reported CNS-related condition results. The median time-to-new onset of any CNS-related conditions was 29.2 months in the ERLEADA cohort.
Literature Search
A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) conducted on 23 October 2026.
| 1 | Reviriego C. ARN-509. Androgen receptor signaling inhibitor, prostate cancer therapy. Drugs Future. 2015;40(2):101-108. |
| 2 | Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494-1503. |
| 3 | Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31(28):3525-3530. |
| 4 | Lledo DS, Patel C, Joshi K, et al. Real-world assessment of new-onset central nervous system conditions in patients with non-metastatic castration resistant prostate cancer treated with apalutamide, darolutamide, or enzalutamide. Poster presented at: Society of Urologic Oncology (SUO) Annual Meeting; December 2-5, 2025; Phoenix, AZ. |